Safety of antiandrogen therapy for treating prostate cancer. Expert opinion on drug safety. By Ricci et al 2014

Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial. By Winters-Stone et al 2015

Subjective and Objective Effects of Androgen Ablation Therapy on Voice. By Salturk et al 2015

The role of intermittent androgen deprivation therapy in the management of biochemically recurrent or metastatic prostate cancer. By Jaswal and Crook 2015

Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer. By O’Farrell et al 2015

Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong. By Teoh et al 2015 

Effects of a luteinizing hormone-releasing hormone agonist on cognitive, sexual, and hormonal functions in patients with prostate cancer: relationship with testicular and adrenal androgen levels. By Okamoto et al 2015 

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. By Karmin et al 2015 

Bisphosphonate prescriptions in men with androgen deprivation therapy use. By Gulamhusein et al 2015

Effectiveness of Androgen-Deprivation Therapy and Radiotherapy for Older Men With Locally Advanced Prostate Cancer. By Bekelman et al 2015